Long-Term Side Effects of Mounjaro: What the Evidence Shows

What do the clinical trial data actually show over time?

SURMOUNT-1, the largest pivotal trial for tirzepatide in weight management, ran for 72 weeks and involved 2,539 adults with obesity. It remains the primary source of extended safety data available before real-world use. Over that period, the most frequently reported side effects were gastrointestinal, including nausea, vomiting, diarrhoea, constipation, and indigestion. Critically, these were most intense at the start of treatment or after a dose increase, and in the majority of participants they eased considerably as the body adjusted. That pattern is consistent with how the medicine slows gastric emptying.

Beyond the gut, SURMOUNT-1 and the broader programme recorded injection-site reactions, fatigue, dizziness, and headache. Serious adverse events were infrequent. Gallbladder-related events (including gallstones) appeared at a higher rate than in the placebo group, a finding consistent with other GLP-1 and weight-loss medicines where rapid fat reduction can increase bile concentration. This is documented in the NHS medicines page for tirzepatide, and it is worth knowing about before starting.

One practical habit worth building from week one: check the injection site after each dose. Persistent redness, swelling or hardening that doesn't settle between injections is worth flagging to your prescriber sooner rather than later. It takes under a minute and catches early injection-site reactions before they become uncomfortable.

What the trials cannot yet answer is what happens beyond 72 weeks in large populations. That is precisely why the Black Triangle monitoring exists, and why ongoing post-marketing evidence on Mounjaro's longer-term safety will continue to accumulate over the coming years.

Is the thyroid concern from animal studies relevant to people?

The Mounjaro prescribing information includes a precaution about thyroid C-cell tumours. This comes from rodent studies in which tirzepatide, like other GLP-1 receptor agonists, caused dose-dependent increases in thyroid C-cell tumours. It is a reasonable question to ask about, and it deserves a straight answer.

Rodent thyroid tissue responds to GLP-1 receptor stimulation differently from human thyroid tissue. The mechanism that drives these findings in rats and mice is not known to operate in the same way in people. To date, no causal link between tirzepatide and thyroid C-cell tumours in humans has been established. However, because the theoretical concern exists, the medicine is not recommended for anyone with a personal or family history of medullary thyroid carcinoma, or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Your prescriber will ask about this during assessment.

If you want to read the exact wording of this precaution and the full contraindications list, the Mounjaro Summary of Product Characteristics on the eMC sets it out in full. It is publicly accessible and worth reading alongside any content you find online, including this page.

The broader question of how to weigh up Mounjaro's long-term risk profile is one our prescribers work through with every patient individually, because the balance looks different depending on your starting health.

When do long-term symptoms need urgent medical attention?

Most side effects that emerge over months of treatment are mild and manageable, but a few warrant prompt contact with a doctor. The MHRA's Drug Safety Update issued in January 2026 specifically highlighted acute pancreatitis as a risk requiring vigilance: severe stomach pain that persists and spreads towards the back, especially if accompanied by vomiting, should lead you to seek medical help that day, not wait for your next check-in.

Other symptoms to take seriously at any point in treatment include: signs of gallbladder trouble (pain in the upper right abdomen, particularly after eating); significant dehydration following prolonged vomiting or diarrhoea; an allergic reaction (swelling of the face, lips or throat, difficulty breathing); and any sudden change in vision, which may warrant an eye check if you have diabetes-related eye disease. Persistent low mood or thoughts of self-harm are also listed as symptoms to report.

None of these are common. The reason they appear in guidance is not to alarm, but because catching them early makes a real difference. If you want to understand what to watch for from the beginning of treatment, our guide to Mounjaro side effects covers the full picture, and any suspected new side effect (however minor it seems) can be reported to the MHRA through the Yellow Card scheme.

If you are already on treatment and have a question about something you have noticed, our aftercare team is available seven days a week.

Does treatment duration change the risk picture?

NICE's appraisal of tirzepatide (TA1026) does not impose a maximum treatment duration, unlike the NICE recommendation for injectable semaglutide which is currently capped at two years within specialist services. That distinction reflects the difference in how the evidence bases matured and how the two appraisals were structured, not a statement that tirzepatide is definitively safer over decades. Long-term use beyond the trial period remains a shared decision between you and your prescriber, revisited each time a repeat supply is considered.

Stopping treatment is also not without consequence. Weight regain is documented after discontinuation, and how quickly it occurs varies between individuals. This is not a reason to stay on treatment indefinitely regardless of clinical review, it is a reason to ensure those reviews actually happen. At nume, our clinical team re-assesses every patient before each repeat prescription, rather than auto-renewing supply without review.

People searching for context on what long-term Mounjaro side effects look like in practice, or wondering whether Mounjaro has confirmed long-term side effects, will find the evidence base is genuinely still building, which makes clinical oversight during treatment more important, not less. Our prescribers discuss all of this as part of the consultation; if you would like to talk through suitability, starting a free consultation is the right first step.